ML20069B154
| ML20069B154 | |
| Person / Time | |
|---|---|
| Site: | SHINE Medical Technologies, 99902034 |
| Issue date: | 02/24/2020 |
| From: | SHINE Medical Technologies |
| To: | Office of Nuclear Reactor Regulation |
| Shared Package | |
| ML20069B152 | List: |
| References | |
| 2020-SMT-0020 | |
| Download: ML20069B154 (35) | |
Text
34 pages follow ENCLOSURE 2 SHINE MEDICAL TECHNOLOGIES, LLC MEETING SLIDES FOR THE MARCH 4 AND 5, 2020 PUBLIC MEETING BETWEEN SHINE MEDICAL TECHNOLOGIES, LLC AND THE NRC TRITIUM PURIFICATION SYSTEM (TPS) DESIGN CHANGE PUBLIC VERSION
Tritium Purification System (TPS)
Design Change Neil Roberts, Nuclear Engineer
SHINE Medical Technologies l 2 I.
High-Level TPS Overview II.
Current FSAR-Described TPS Design III.
New TPS Design IV.
Summary of Safety Improvements V.
Licensing Basis Impacts VI.
Summary
High-Level TPS Overview
SHINE Medical Technologies l 4 Neutron driver assembly system (NDAS) units accelerate a deuterium ion beam into a tritium gas target.
High tritium concentrations are required in the target to meet neutron production requirements, so a means to provide constant high purity tritium to the target is required.
The tritium purification system (TPS) provides a constant supply of high purity tritium through isotopic separation of tritium and deuterium from NDAS target chamber exhaust.
The core TPS technology for isotope separation is the thermal cycling absorption process (TCAP), which separates deuterium and tritium into high purity tritium and deuterium streams.
Supporting subsystems include impurity removal and glovebox cleanup subsystems.
TPS High Level Overview
SHINE Medical Technologies l 5 1.
Mixed tritium-deuterium gas is fed to the palladium-based separation column 2.
The palladium-based column is heated while the molecular sieve column is cooled, moving gas between the columns, then the process is reversed 3.
Tritium collects at the end of the palladium-based column, and deuterium collects at the end of the molecular sieve column 4.
Operates in a batch process using a set of buffer volumes for continuous recovery and delivery from NDAS 5.
High purity tritium is collected in a product tank 6.
Tritium is delivered to NDAS units to keep high concentrations of tritium in the NDAS target chamber required to meet neutron output requirements TCAP Overview
SHINE Medical Technologies l 6 New design substantially improves reliability of system and reduces single-point operational failures Design improvements remove some accident scenarios in SHINE safety analysis and improve overall system safety Improved process equipment design reduces maintenance frequency and complexity Drivers for Change to the TPS Design
Current FSAR-Described TPS Design
SHINE Medical Technologies l 8 One train of isotope separation equipment serves all eight NDAS units simultaneously.
High purity tritium and deuterium are supplied to the accelerator TPS interface system (ATIS) header.
The ATIS header supplies process equipment confined in ATIS interface gloveboxes to regulate the flow of gas into and out of each NDAS.
A single glovebox cleanup system serves the main TPS glovebox and eight interface glovebox atmospheres.
Current FSAR-Described TPS Design
SHINE Medical Technologies l 9 Vacuum pumps recover gas from above-ground NDAS exhaust return header.
Liquid nitrogen cooled carbon bed captures impurities before TCAP inlet.
TCAP separates mixed tritium and deuterium into pure tritium and deuterium streams.
The TCAP tritium and deuterium streams are pumped to the ATIS header.
Interface equipment (ATIS) regulates the flow of tritium to the NDAS target chamber and deuterium to the NDAS ion source from the ATIS header.
A pump pushes gas from the NDAS target chamber exhaust back to vacuum pumps at the start of the isotope separation process through the ATIS header.
Current FSAR-Described TPS Isotope Separation Process
SHINE Medical Technologies l10 The glovebox stripper system (GBSS) removes tritium contamination from the central TPS glovebox atmosphere and the eight interface glovebox atmospheres.
The GBSS converts tritium to tritiated water and captures the tritiated water on molecular sieve beds.
The GBSS recirculates the central TPS glovebox atmosphere and is single-pass for the eight interface gloveboxes using a continual purge to facility ventilation.
The GBSS also treats waste gas from process line evacuations before and after equipment maintenance.
Current FSAR-Described TPS Glovebox Cleanup System
SHINE Medical Technologies l11 Current FSAR-Described TPS Layout SRI Security-Related Information - Withheld Under 10 CFR 2.390(d)
SHINE Medical Technologies l12 Current FSAR-Described TPS Layout Security-Related Information - Withheld Under 10 CFR 2.390(d)
New TPS Design
SHINE Medical Technologies l14 Three train design replaces single train Removal of interface gloveboxes and above-ground tritium header External deuterium source for NDAS Improvements in glovebox cleanup system design and reliability Improvements in process equipment design and operating philosophy New TPS Design Overview
SHINE Medical Technologies l15 Replaced the single isotope separation train with three trains Trains operate independently of each other; NDAS units remain independent of each other West wall of TPS room moved to ensure adequate space for TPS equipment Each train has dedicated equipment for glovebox atmosphere cleanup and process line evacuation Total facility tritium inventory unchanged Three Train Configuration PROP/ECI Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
SHINE Medical Technologies l16 TPS Room Layout Security-Related Information - Withheld Under 10 CFR 2.390(d)
SHINE Medical Technologies l17 Process lines run directly from the TPS room to each NDAS through subgrade penetrations, removing the need for interface gloveboxes above each IU cell.
Removal of the ATIS interfaces and switch to subgrade penetrations removes the need for an above-ground tritium supply header.
Process lines are guarded from mechanical impact within subgrade penetrations and through barriers installed around tubing from glovebox to subgrade penetrations.
Removal of Accelerator TPS Interface System (ATIS)
SHINE Medical Technologies l18 Interface between TPS and NDAS Security-Related Information - Withheld Under 10 CFR 2.390(d)
SHINE Medical Technologies l19 Deuterium supply to NDAS provided through an external supply bottles instead of through the deuterium side of TCAP.
Deuterium supplied to NDAS ion source exhausts to facility ventilation instead of recycling deuterium back to TCAP.
Reduces load on isotope separation equipment, reducing component size and system complexity.
Deuterium Supply to NDAS
SHINE Medical Technologies l20 New TPS design uses a secondary enclosure cleanup (SEC) system to clean glovebox atmospheres, separate from the process line evacuation equipment.
Switched glovebox inert gas atmosphere from nitrogen to helium SEC design captures both tritiated water and elemental tritium rather than converting tritium to water for capture.
Dedicated SEC system for each glovebox improves the reliability of TPS.
Glovebox Cleanup System Design
SHINE Medical Technologies l21 Use of cryopumps instead of vacuum pumps, improving performance while reducing maintenance requirements A palladium-based permeator replaces activated carbon bed for impurity removal, improving operability and improving system safety TCAP deuterium stream directed to impurity treatment system instead of recycled to NDAS Flow controllers connect TPS directly to NDAS units, replacing the ATIS and associated header lines Process line evacuation separate from glovebox cleanup system, reducing normal contamination levels in gloveboxes and improves reliability of overall system New Process Equipment
Summary of Safety Improvements
SHINE Medical Technologies l23 Improved design eliminates above ground tritium supply header and associated risk of damage to interface lines Removal of ATIS gloveboxes reduces maintenance challenges and potential worker dose Eliminates accident scenario related to unintended exothermic chemical reactions other than detonation with removal of activated carbon bed Improvements in process design and operation concepts reduce equipment failure modes and maintenance requirements, improves reliability and availability of system Safety Improvements with new TPS Design
Licensing Basis Impacts
SHINE Medical Technologies l25
FSAR Chapter 1
Figures 1.3-1 and 1.3-2 updated to reflect moving west wall of TPS room
FSAR Chapter 4
Figure 4a2.1-1 updated to reflect direct connections between TPS gloveboxes and the NDAS
Section 4a2.3 updated to reflect source of deuterium and update nominal flowrate values for tritium supply and mixed gas return
FSAR Chapter 6
Figure 6a2.1-1 updated to reflect active and passive components of new TPS design
Table 6a2.1-2 updated to reflect new calculated unmitigated and mitigated dose results for the representative tritium confinement boundary design basis accident
Section 6a2.2 updated to describe new tritium confinement boundary and remove reference to ATIS
Figure 6a2.2-1 updated to remove connections to ATIS and update IU cell confinement boundary
Figure 6a2.2-2 updated to reflect new tritium confinement boundary for TPS and to add connection from the NDAS to RVZ1e Licensing Basis Impacts
SHINE Medical Technologies l26
FSAR Chapter 7
Section 7.4 updated to provide a description of the new IU Cell TPS Actuation safety function
Section 7.4 updated to remove ATIS components as primary confinement boundary components and add new TPS isolation valves to the listing of primary confinement boundary components
Section 7.4 updated to remove discussion of monitoring of the ATIS mixed gas return line, including associated operational bypasses, permissives, and interlocks
Table 7.4-1 updated to remove ATIS mixed gas return line tritium concentration as a monitored variable
Table 7.4-1 updated to replace the ATIS gas return line pressure with the TPS target chamber exhaust pressure as a monitored variable
Figure 7.4-1 updated to reflect new TRPS logic diagrams
Section 7.5 updated to provide a description of the new TPS Process Vent Isolation safety function
Section 7.5 updated to describe individual TPS train isolations
Table 7.5-1 updated to include individual glovebox tritium concentrations as monitored variables and to increase the analytical limit for tritium concentration in the TPS exhaust to facility stack from 80 µCi/m3 to 1 Ci/m3 Licensing Basis Impacts
SHINE Medical Technologies l27
FSAR Chapter 7 (continued)
Table 7.5-2 updated to reflect the fail safe component positions for new TPS components
Figure 7.5-1 updated to reflect new ESFAS logic diagrams
Figure 7.5-4 updated to reflect TPS isolation interface for radiologically controlled area (RCA) isolation
Section 7.7 updated to reflect new radiation monitoring locations with the TPS and associated actuation signals
FSAR Chapter 8
Section 8a2.2 updated to include the TPS SEC system heaters as standby generator system (SGS) loads
Table 8a2.2-1 updated to remove GBSS blowers and heaters from the uninterruptible electrical power supply system (UPSS) load list and add TPS SEC system blowers to the list
Table 8a2.2-2 updated to remove GBSS blowers and heaters from the UPSS battery sizing and add TPS SEC system blowers to the sizing
FSAR Chapter 9
Section 9a2.1 updated to reflect interface of the radiological ventilation systems with the new TPS design
Section 9a2.7 updated to reflect new TPS design, addressing the three train configuration and removal of the ATIS gloveboxes from the design Licensing Basis Impacts
SHINE Medical Technologies l28
FSAR Chapter 9 (continued)
Section 9a2.7 updated to replace the description of the ATIS header with a description of the subgrade process connections
Section 9a2.7 updated to replace the description of the GBSS with a description of the SEC system
Section 9a2.6 updated to describe the new tritium purification process sequence
Table 9a2.7-1 updated to reflect the modified interface of the TPS with the facility nitrogen handling system and add the interface of the TPS with the SGS
Table 9a2.7-2 updated to reflect the new TPS design nominal flow rates
Table 9a2.7-3 updated to reflect the new TPS design process equipment
Figure 9a2.7-1 updated to show the new TPS design process flow and isolation valve locations
Section 9b.7 updated to reflect the modified interface of the facility nitrogen handling system with the TPS
FSAR Chapter 11
Section 11.1 updated to reflect the treatment of releases from the TPS via the SEC system
Table 11.1-5 updated to reflect the three train configuration of the new TPS design Licensing Basis Impacts
SHINE Medical Technologies l29
FSAR Chapter 13
Subsection 13a2.1.10 (Unintended Exothermic Chemical Reactions other than Detonation) updated to remove Scenario 2, which involved the ignition of the activated carbon bed in the TPS
Subsection 13a2.1.11 (System Interaction Events) updated to reflect the new TPS design in the loss of ventilation functional interaction description
Subsection 13a2.1.12 (Facility-Specific Events) updated to reflect the new TPS design in the description of initial conditions for accident scenarios involving the TPS, including replacing nitrogen with helium as the glovebox atmosphere inerting gas
Subsection 13a2.1.12 (Facility-Specific Events) updated to reflect the new TPS design within the TPS Scenario descriptions
Subsection 13a2.1.12 (Facility-Specific Events), TPS Scenario 5 (Release of Tritium into the IF due to TPS Interface Line Mechanical Damage) updated to reflect the scenario as not credible due to the subgrade routing of TPS process lines protected from mechanical damage
Subsection 13a2.2.10 (Unintended Exothermic Chemical Reactions other than Detonation) updated to remove Scenario 2, which involved the ignition of the activated carbon bed in the TPS Licensing Basis Impacts
SHINE Medical Technologies l30
FSAR Chapter 13 (continued)
Subsection 13a2.2.12 (Facility-Specific Events) updated to reflect the new TPS design in the sequence of events related to the release of tritium into an IU cell
Subsection 13a2.2.12 (Facility-Specific Events) updated to reflect the new TPS design in the sequence of events related to the tritium release into the TPS glovebox, including the three train configuration of the TPS gloveboxes
Subsection 13a2.2.12 (Facility-Specific Events) updated to increase the initial material at risk for the tritium release into the TPS glovebox from 236,000 Ci to 300,000 Ci
Subsection 13a2.1.12 (Facility-Specific Events) updated to remove the analysis of the tritium release into the irradiation facility, as the scenario, involving a break in the ATIS tritium header, was eliminated as a result of the new TPS design
Table 13a2.2-1 updated to reflect new public radiation transport terms (ARF x LPF) for the tritium release into the TPS glovebox event and remove the tritium release into the irradiation facility event
Table 13a2.2-2 updated to reflect new worker radiation transport terms (ARF x LPF) for the tritium release into the TPS glovebox event and remove the tritium release into the irradiation facility event
Table 13a3-1 updated to reflect new dose consequences for the tritium release into the TPS glovebox event and remove the tritium release into the irradiation facility event Licensing Basis Impacts
SHINE Medical Technologies l31
Technical Specifications
LCO 3.2.1 updated to include the IU Cell TPS Actuation in the table of TRPS Actuation Functions
LCO 3.2.2 updated to reflect the three train configuration of the new TPS design and to include the TPS Process Vent Isolation in the table of ESFAS Actuation Functions
LCO 3.3.3 updated to remove the [
]PROP/ECI and the driver dropout [
]PROP/ECI from the table of TRPS Interlocks
LCO 3.2.5 updated to reflect the removal of the ATIS, including the removal of the monthly channel check of the ATIS mixed gas return line tritium concentration monitors
LCO 3.4.1 updated to remove ATIS components as primary confinement boundary components and add new TPS isolation valves to the table of primary confinement boundary isolation valves and dampers
LCO 3.4.3 updated to reflect the three train configuration of the new TPS design and to identify new TPS isolation valves the in the table of TPS glovebox confinement valves
LCO 3.6.1 updated to reflect the three train configuration of the new TPS design
LCO 3.7.1 updated to reflect the three train configuration of the new TPS design and to identify radiation monitoring locations and setpoints within the new TPS Licensing Basis Impacts Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
SHINE Medical Technologies l32
Technical Specifications (continued)
LCO 3.8.7 updated to reflect the three train configuration of the new TPS design, to reflect replacing nitrogen with helium as the glovebox atmosphere inerting gas, and to reflect replacing monitoring of the glovebox atmosphere for oxygen concentration with monitoring the dew point
LCO 3.8.8 updated to reflect the three train configuration of the new TPS design and replacing the GBSS with the SEC system
LCO 3.8.9 updated to identify the TPS ventilation supply and exhaust dampers in the table of RCA isolation dampers
Program 5.5.4 updated to include protection from external impact damage of TPS-NDAS interface lines by either running of the lines in subgrade sleeves protected by rebar reinforced concrete or by mechanical guards on the above grade portions of the lines in the TPS room Licensing Basis Impacts
Summary
SHINE Medical Technologies l34 New design substantially improves reliability of system and reduces single-point operational failures Design improvements remove some accident scenarios in SHINE safety analysis and improve overall system safety SHINE plans to submit revised licensing basis documents (i.e., Final Safety Analysis Report and Technical Specifications) the week of March 9th, 2020, reflecting the new TPS design Summary of the TPS Design Change